Shaanxi Micot interim net loss widens 364.3% to RMB 231.7 million in FY26 H1

• Shaanxi Micot Pharmaceutical posted an interim IFRS net loss of RMB 231.68 million, widening 364.3% year over year.
• R&D spending more than tripled to RMB 127.73 million, driving a deeper loss as clinical programs advanced.
• Net cash from operating activities swung to an inflow of RMB 109.18 million, helped by a RMB 200 million upfront payment from Everest.
• Cash and financial assets climbed to RMB 1.23 billion, up 355.2%, supported by the Everest payment and global offering proceeds.
• MT1013 completed Phase III enrollment; database lock targeted in Q4 2026, with NDA filing expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shaanxi Micot Pharmaceutical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12303896), on August 28, 2026, and is solely responsible for the information contained therein.